Description

Zotarolimus is a semi-synthetic derivative of sirolimus (rapamycin) and a potent mTOR inhibitor. This compound is of significant commercial and research interest due to its primary application as the active pharmaceutical ingredient (API) in drug-eluting stents for cardiovascular interventions. It is essential for manufacturers in the pharmaceutical and advanced medical device sectors seeking a high-purity, reliable supply for critical therapeutic applications. Zotarolimus CAS NO 221877-54-9 is a key component in products designed to prevent restenosis following angioplasty procedures.

Application

• Drug-Eluting Stents (DES): Primary active ingredient in coronary and peripheral vascular stents to inhibit smooth muscle cell proliferation and prevent restenosis.
• Pharmaceutical Research: Used as a reference standard and building block in R&D for novel mTOR-targeting oncology and immunosuppressive therapies.
• API Manufacturing: Serves as the critical raw material for the synthesis and formulation of finished pharmaceutical products.
• Biomedical Coatings: Incorporated into polymer matrices for controlled-release coatings on various implantable medical devices.
• Cell Biology Studies: A vital tool compound for investigating the mTOR signaling pathway in academic and industrial research settings.

Basic Information

Product Name	Zotarolimus
CAS No.	221877-54-9
Molecular Formula	C52H84N4O12
Molecular Weight	957.25 g/mol
Synonyms	ABT-578; Ariadne; Everolimus Impurity; (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; mTOR Inhibitor
EINECS	Contact for details

Quality Control

Our Zotarolimus is manufactured under strict quality management systems. Each batch undergoes comprehensive analytical testing to ensure it meets stringent specifications for pharmaceutical use, including identity, purity, and impurity profile. Certificates of Analysis (COA) are provided with each shipment, detailing results from validated methods such as HPLC, NMR, and MS. We support compliance with cGMP, ICH Q7, and relevant pharmacopeial standards (USP/EP) for active pharmaceutical ingredients.

Storage

Preserve in a tightly closed container, protected from light. Store at controlled room temperature, typically between 15°C and 25°C, in a dry environment. The product is light-sensitive (store away from light). For long-term storage, consider conditions of 2-8°C. Keep the container sealed to protect from moisture.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥ 98.0%
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single impurity ≤ 1.0%
Water Content (KF)	≤ 1.0%
Residue on Ignition	≤ 0.1%
Heavy Metals	≤ 20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.